about
Monocytes from depressed patients display an altered pattern of response to endotoxin challengeDetection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells.The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes.mTOR kinase: a possible pharmacological target in the management of chronic pain.The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis.Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep-2 laryngeal cancer cells.The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis.Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis.Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.Interactions between integrase inhibitors and human arginase 1.Antiretrovirals inhibit arginase in human microglia.The activation of type 1 corticotropin releasing factor receptor (CRF-R1) inhibits proliferation and promotes differentiation of neuroblastoma cells in vitro via p27(Kip1) protein up-regulation and c-Myc mRNA down-regulation.Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.Optimal Solubility of Diclofenac β-Cyclodextrin in Combination with Local Anaesthetics for Mesotherapy Applications.Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis.Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.Variability of raltegravir plasma levels in the clinical setting.Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (AtazanaThe mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype.AMPA- and P2X7-receptor-mediated facilitation of [3H]D-aspartate release from nerve terminals isolated from the rat caudal brainstem.Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples.Flupirtine antinociception in the rat orofacial formalin test: an analysis of combination therapies with morphine and tramadol.Antiretroviral agents increase NO production in gp120/IFNγ-stimulated cultures of rat microglia via an arginase-dependent mechanism.Trigeminal satellite cells modulate neuronal responses to triptans: relevance for migraine therapy.Linezolid use in ventilator-associated pneumonia: look at the body weight of your patient!Correlation between algogenic effects of calcitonin-gene-related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin-induced sensitization.Cortistatin modulates the expression and release of corticotrophin releasing hormone in rat brain. Comparison with somatostatin and octreotide.The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids.Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interactionThe role of small intestinal bacterial overgrowth in Parkinson's diseaseTapentadol inhibits calcitonin gene-related peptide release from rat brainstem in vitroInfluence of the Oral Dissolution Time on the Absorption Rate of Locally Administered Solid Formulations for Oromucosal Use: The Flurbiprofen Lozenges ParadigmTrigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1β pro-inflammatory effects
P50
Q28484837-65161B4B-9EDE-4F82-B221-459E136ADB0FQ30758299-A3B450E1-3DE1-4F74-B555-9C0679F46EA7Q33580909-081EA3CC-356B-4A9D-890F-233247E9B277Q34515338-0371FA05-C9AE-444D-A016-35EAAC074F8DQ35035474-3708743C-6E5C-4906-90F1-CA9DA3BD5168Q35083824-74939855-9B4F-4956-B73B-0CB1211E1989Q35263472-8AD3AB80-692D-46FD-B422-E04E6E91BECEQ37010253-23D6B562-2E85-4942-9F74-1A470C43E093Q37678646-AEE7702A-9D4C-4EAD-B41B-35714D9A355FQ37935254-4E34AFF3-D24F-41F8-BDC8-3D2135BAC768Q38050335-A1BFF210-3110-49F2-B03C-75BDE6118EF8Q38330960-9E8A9DB9-94FD-4BEA-BBBC-D3E49BAA5E74Q38708124-D66F8B57-A651-45E9-BF84-C4BF14846C0AQ38827989-6597B901-28E1-46DF-A8A1-907F072CE733Q38876975-A6A5EE6B-075C-4628-A55A-2BE45278210DQ41021229-FBB35B37-2720-4D35-943D-A3858816CC81Q41512202-3505D0A4-5C95-4DB7-94AF-8AAB409546E6Q41654159-E5A22896-4F8F-4780-9CCB-A71C2F9C933EQ41989456-96771987-A89A-48C4-B569-6787EB8C1689Q42224074-9B855827-F012-4B8E-A320-699C01FB4048Q42228170-C51F116F-9E1F-43F0-B463-679E5969EAA8Q42253719-CFE69749-FD7A-4ABA-9E62-D07923A576DDQ42276740-647915DA-2353-4A21-8743-0C5722A3B34CQ42462727-805D3446-BDA8-4FEF-9BD9-A8BF313E8342Q42951011-316AF640-BA31-467B-BD67-ECB583A82C3DQ43157237-BECAFFA4-9318-458B-B0FE-3D1B79898692Q44393316-2F9AC47A-3EDC-41FC-9899-FA6F59C3381FQ44706242-7310196D-FDDD-475E-8563-F12DB4E821F6Q45887414-3649832C-D3F3-4F0F-BBF5-7F553711CE58Q46080976-7A415DE1-2A4B-4F81-A355-C412D4829255Q46495708-FFAB6599-AEF4-4A32-BEAE-38D24E580BDEQ47293792-2A8768FF-4801-466E-8388-45F83D9BCDE0Q47994217-830A2222-D87E-456F-8C61-2BE6353DCD56Q48656313-154BC04A-0339-460D-9400-CDA251076C5DQ51309990-EAC7D1E1-03A5-4A9D-AD3C-4BAB65F8F746Q58480316-CFE8ECBC-8DDC-4DA2-8EA8-697A1CEC344CQ59153400-56BA4F43-0A80-4479-895A-832E11305B7CQ59706086-71F33244-8BA8-4F3F-AB26-76046CE5F39BQ59706100-8C0B6D1B-3B77-4D10-94E7-CA0B22AAE19FQ59706143-ECCAE9CB-A012-42F1-A12A-89A1FC87B8A6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pierluigi Navarra
@ast
Pierluigi Navarra
@en
Pierluigi Navarra
@es
Pierluigi Navarra
@nl
type
label
Pierluigi Navarra
@ast
Pierluigi Navarra
@en
Pierluigi Navarra
@es
Pierluigi Navarra
@nl
prefLabel
Pierluigi Navarra
@ast
Pierluigi Navarra
@en
Pierluigi Navarra
@es
Pierluigi Navarra
@nl
P106
P31
P496
0000-0002-4424-650X